PT - JOURNAL ARTICLE AU - Carolin Gabbert AU - Inke R. König AU - Theresa Lüth AU - Beke Kolms AU - Meike Kasten AU - Eva-Juliane Vollstedt AU - Alexander Balck AU - Fox Insight Study AU - Anne Grünewald AU - Christine Klein AU - Joanne Trinh TI - Coffee, smoking and aspirin are associated with age at onset and clinical severity in idiopathic Parkinson’s disease AID - 10.1101/2021.11.08.21265971 DP - 2021 Jan 01 TA - medRxiv PG - 2021.11.08.21265971 4099 - http://medrxiv.org/content/early/2021/11/09/2021.11.08.21265971.short 4100 - http://medrxiv.org/content/early/2021/11/09/2021.11.08.21265971.full AB - Parkinson’s disease (PD) is a progressive neurodegenerative disorder. Genetic modifiers, environmental factors and gene-environment interactions have been found to modify PD risk and disease progression. The objective of this study was to evaluate the association of smoking, caffeine and anti-inflammatory drugs with age at onset (AAO) and clinical severity in a large PD cohort. A total of 35,963 American patients with idiopathic PD (iPD) from the Fox Insight Study responded to health and lifestyle questionnaires. We compared the median AAO between different groups using the non-parametric Mann-Whitney U test. Non-parametric Spearman correlation was used for correlation assessments and regression analysis was used to assess interaction between variables. Reported p-values remain descriptive because they are not corrected for multiple testing and results are exploratory. We found that smoking (r=0.08, p<0.0001), coffee drinking (r=0.69, p<0.0001) and aspirin intake (r=0.23, p<0.0001) show an exploratory association with AAO in iPD. However, the effect of aspirin diminished as an independent predictor after including comorbidities (heart diseases and arthritis). Smoking was associated with higher (more severe) motor scores, while coffee drinking was linked to lower (less severe) motor scores (p<0.05). In addition, smokers reported anxiety, depression and other non-motor symptoms such as unexplained pains and problems remembering (p<0.05). The association of aspirin with PD AAO was replicated in another cohort (EPIPARK) (n=237 patients with PD), although again the effect diminished after including age in the regression model. Future longitudinal studies are warranted to investigate the clinical severity over time.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Fox Insight Study (FI) is funded by The Michael J. Fox Foundation for Parkinson's Research. We would like to thank the Parkinson's community for participating in this study to make this research possible. This study was funded by The Michael J. Fox Foundation for Parkinson's Research (Analysis of Patient-Reported Outcomes from Fox Insight). JT, MK, and CK are supported by the DFG (FOR 2488).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We were granted access to de-identified phenotypic data of Fox Insight through a Data Use Agreement. Our local ethics committee of the University of Luebeck further stated that there are no objections to the analysis of completely anonymized data and the study does not require ethical oversight (file number 21-328, 29th July 2021).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in the preparation of this article were obtained from the Fox Insight database (https://foxden.michaeljfox.org/insight/explore/fox.jsp) on 18/10/2020. For up-to-date information on the study, visit https://foxden.michaeljfox.org/insight/explore/fox.jsp.